ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2214

Lung Involvement in Primary Sjögren’s Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings

Janet Flores1, Diego Baenas2, Nadia Riscanevo3, Emanuel Saad4, Maria Jezabel Haye Salinas5, Soledad Retamozo6, Ana C. Alvarez5, Alejandro Alvarellos7, Juan Pablo Pirola8, Nadia Benzaquén5, Verónica Saurit9 and Francisco Caeiro8, 1Rheumatology Unit, Hospital privado Universitario de Córdoba, Cordoba, Argentina, 2Reumatologia, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 3Rheumatology, Rheumatology Unit, Hospital privado Universitario de Córdoba, Cordoba, Argentina, 4Internal medicine, Hospital Privado, Cordoba, Argentina, 5Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, 6Sociedad Argentina de Reumatologia, Córdoba, Argentina, 7Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 8Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 9Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Pulmonary Involvement, Sjogren's syndrome and computed tomography (CT)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Imaging of Rheumatic Diseases Poster III: Other Modalities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease that affects exocrine glands. It can generate pulmonary compromise due to dysfunction of the glandular epithelium of the airway.

To know the prevalence of pulmonary involvement in patients with pSS in our environment; to detail clinical characteristics associated with pulmonary involvement; to compare demographic, clinical, serological and therapeutic characteristics of patients with and without pulmonary involvement in pSS.

Methods: Retrospective descriptive study. Patients diagnosed with pSS (American-European criteria 2002) were included from 2010 to 2017. Abnormal salivary gland biopsy (SGB) was considered to grades III and IV of the Chisholm and Mason classification.Multivariate analyzes were performed comparing pSS with pulmonary involvement versus pSS without this involvement; p <0.05 value was considered statistically significant. The results were analyzed with the software SPSS 19.0.

Results: 197 patients were included, 180 (90%) were women. The mean age at diagnosis was 54 ± 13.62 years.The most frequent symptoms were xerostomia in 166 (83%) patients and xerophthalmia in 178 (89.0%). In 25 (12.5%) patients, pulmonary involvement was diagnosed by high resolution computed tomography (HRCT), 19 (76%) with interstitial lung disease (ILD) and 6 (24%) with bronchiectasis in the absence of DILD; 21 (10.5%) patients had a history of smoking. The most frequent pattern of ILD was nonspecific interstitial pneumonia (NSIP) in 68.4%, followed by lymphocytic interstitial pneumonia (LIN) and usual interstitial pneumonia (UIP) with 15.78% in both groups.
Erythrocyte sedimentation rate (ESR)> 50 mm/h was observed at the time of diagnosis in 26 (13.0%) patients, and elevated C-reactive protein (CRP) in 22 (11.0%), median value of 0.06 (RIQ 0-0.39). Anemia was observed in 14 (7.0%) patients, leukopenia in 16 (8.0%) and hypergammaglobulinemia in 47/81 (58.0%). SGB was abnormal in 179 (89.5%), grade III in 75 (37.5%) and IV in 104 (52.0%). Regarding treatment, 61 (30.5%) received hydroxychloroquine, 56 (28.0%) prednisone <20 mg / day and only 5 (2.5%) prednisone ≥20 mg / day. Three (1.5%) patients died during the 7 years of follow-up. In the univariate analysis, it was observed that patients with pSS and pulmonary involvement were associated with greater age at the time of diagnosis (61 ± 10.75 vs 53 ± 13.7, p = 0.004), smoking history (40% vs 6, 4%, p <0.001); ESR> 50 mm/h at diagnosis (36% vs 9.9%, p = 0.002), high CRP (36% vs 7.6%, p <0.001), anemia (20% vs 5.3%; p = 0.02), greater use of hydroxychloroquine (60% vs 26.9%, p = 0.002) and greater use of prednisone at doses> 20 mg / day (12% vs 1.2%, p = 0.01) with respect to to patients with pSS without pulmonary involvement. In the multivariate analysis, statistical significance was maintained for smoking (OR: 31, 95% CI: 4.513-212.970, p <0.001) and high CRP (OR: 10.49, 95% CI: 1.609-68.405, p = 0.014).

Conclusion: The pulmonary involvement in pSS was mainly associated with a history of smoking and was observed more frequently in older patients, with high inflammatory parameters and anemia.


Disclosure: J. Flores, None; D. Baenas, None; N. Riscanevo, None; E. Saad, None; M. J. Haye Salinas, None; S. Retamozo, None; A. C. Alvarez, None; A. Alvarellos, None; J. P. Pirola, None; N. Benzaquén, None; V. Saurit, None; F. Caeiro, None.

To cite this abstract in AMA style:

Flores J, Baenas D, Riscanevo N, Saad E, Haye Salinas MJ, Retamozo S, Alvarez AC, Alvarellos A, Pirola JP, Benzaquén N, Saurit V, Caeiro F. Lung Involvement in Primary Sjögren’s Syndrome: Spectrum of Pulmonary Abnormalities and Computed Tomography Findings [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/lung-involvement-in-primary-sjogrens-syndrome-spectrum-of-pulmonary-abnormalities-and-computed-tomography-findings/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lung-involvement-in-primary-sjogrens-syndrome-spectrum-of-pulmonary-abnormalities-and-computed-tomography-findings/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology